Abbott Laboratories (NYSE:ABT) Updates Q2 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.250-1.310 for the period, compared to the consensus earnings per share estimate of 1.340. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2026 guidance to 5.380-5.580 EPS.

Abbott Laboratories Stock Performance

NYSE ABT opened at $96.89 on Friday. The firm has a market capitalization of $168.75 billion, a P/E ratio of 27.14, a P/E/G ratio of 1.57 and a beta of 0.79. Abbott Laboratories has a 1-year low of $93.92 and a 1-year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The business’s 50-day simple moving average is $107.89 and its 200-day simple moving average is $118.76.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.6%. Abbott Laboratories’s payout ratio is 67.74%.

Analyst Ratings Changes

Several equities analysts recently commented on the company. BTIG Research reissued a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a research report on Friday. Sanford C. Bernstein reduced their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday. Oppenheimer reduced their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday. JPMorgan Chase & Co. reduced their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Mizuho reduced their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $121.00.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the sale, the executive vice president owned 38,573 shares in the company, valued at $4,458,267.34. This represents a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock worth $353,097 over the last ninety days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in Abbott Laboratories by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 23,434,760 shares of the healthcare product maker’s stock worth $2,936,141,000 after purchasing an additional 188,616 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Abbott Laboratories by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,189,528 shares of the healthcare product maker’s stock valued at $1,652,517,000 after acquiring an additional 52,191 shares during the last quarter. Amundi increased its holdings in shares of Abbott Laboratories by 28.3% in the 4th quarter. Amundi now owns 8,185,642 shares of the healthcare product maker’s stock valued at $1,025,578,000 after acquiring an additional 1,803,975 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Abbott Laboratories by 2.0% in the 3rd quarter. Raymond James Financial Inc. now owns 5,536,178 shares of the healthcare product maker’s stock valued at $741,515,000 after acquiring an additional 107,843 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Abbott Laboratories by 29.7% in the 4th quarter. California Public Employees Retirement System now owns 5,206,580 shares of the healthcare product maker’s stock valued at $652,332,000 after acquiring an additional 1,193,410 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.